Activation of Peripheral Blood CD14+ Monocytes Occurs in Diabetes

  1. Christine Cipolletta1,
  2. Kathryn E. Ryan2,
  3. Elinor V. Hanna2 and
  4. Elisabeth R. Trimble12
  1. 1Department of Clinical Biochemistry and Metabolic Medicine, Queen’s University, Belfast, U.K
  2. 2Royal Group of Hospitals, Belfast, U.K
  1. Address correspondence and reprint requests to Christine Cipolletta, Department of Clinical Biochemistry and Metabolic Medicine, Queen’s University Belfast, Institute of Clinical Science A, Grosvenor Road, Belfast BT12 6BJ, U.K. E-mail: ccipollettadaly{at}yahoo.fr or e.trimble{at};gub.ac.uk

Abstract

Blood levels of inflammatory markers associated with endothelial dysfunction and atherosclerosis are increased in diabetic patients; the highest levels occur in poorly controlled diabetes. We investigated the activation state of peripheral blood monocytes in diabetes with respect to scavenger receptor (CD36) expression and monocyte chemoattractant protein-1, intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and peroxisome proliferator–activated receptors mRNA expression. CD14+ monocytes were isolated from peripheral blood of type 1 and type 2 diabetic patients with good (HbA1c <7.0%) or poor (>9.4%) glycemic control and a group of nondiabetic subjects. Monocytes from diabetic subjects displayed increased CD36 cell surface expression (P < 0.0005) and increased uptake of oxidized LDL (P < 0.05). Monocyte chemoattractant protein-1 gene expression was increased in monocytes from both groups of diabetic subjects (P < 0.05). Both CD68 and peroxisome proliferator–activated receptor-γ gene expression were increased in the poorly controlled diabetic group (P < 0.05 for each), whose monocytes also displayed increased attachment to endothelial monolayers (P < 0.0005 vs. nondiabetic control subjects). In poorly controlled diabetes, CD14+ monocytes are functionally activated and show some of the differentiation markers associated with macrophages. These monocytes also demonstrate an increased ability for attachment to normal endothelial cells, one of the early stages in atherogenesis.

Footnotes

  • 15d-PGJ2, 15-deoxy-δ 12, 14 prostaglandin J2; AGE, advanced glycation end product; CMFDA, 5-chloromethylfluorescein diacetate; CRP, C-reactive protein; DiI, 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate; HAoEC, human aortic endothelial cell; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; oxLDL, oxidized LDL; VCAM-1, vascular cell adhesion molecule-1.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 1, 2005.
    • Received January 20, 2005.
« Previous | Next Article »Table of Contents